• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Chronic Obstructive Pulmonary Disease (COPD): KOL Insights on Treatment Practices and Unmet Needs Product Image

Chronic Obstructive Pulmonary Disease (COPD): KOL Insights on Treatment Practices and Unmet Needs

  • ID: 1939592
  • October 2011
  • 99 Pages
  • Sociable Pharma

FEATURED COMPANIES

  • AstraZeneca
  • Chiesi
  • GSK
  • Novartis
  • Sandoz
  • Teva
  • MORE

In-depth primary research was conducted in the US and across Europe with seven key opinion leaders to understand how changes will impact therapy use in the future. During the European Respiratory Society's 2011 Annual Congress, opinion was also gauged on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by COPD specialists.

Understand key treatment trends based on the latest KOL insights including:

- Step-up approach to the management of COPD
- ULABA: a rival to LAMA therapy?
- LABA versus LAMA therapy: current and future use

Identify unmet needs, including:

- Managing adherence issues
- Managing patients with very severe COPD
- Treating COPD inflammation
- Management of exacerbations
- Effective treatments for Stage I mild COPD

Key features:

- 2 treatment maps & 6 treatment settings: A visual guide to the treatment of COPD, based on extensive primary and secondary research

- Analysis of current US/EU treatment practices involving 11 drug classes: Inhaled
SABA, Inhaled SAMA, single combination inhaler of SABA + SAMA, Inhaled LABA, Inhaled LAMA, combination inhaler of ICS + LABA, Phosphodiesterase-4 (PDE-4) inhibitor, oral corticosteroids, methylxanthine, antibiotics, alpha-1 antitrypsin augmentation therapy

- 9 unmet needs identified: Based on KOL interviews and literature research

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca
  • Chiesi
  • GSK
  • Novartis
  • Sandoz
  • Teva
  • MORE

Executive Summary
Step-up approach to the management of COPD
LABA vs. LAMA: current and future use
ULABA: a rival to LAMA?
Inhaled corticosteroids: should they be used?
Treatments for exacerbation-prone patients
Targeting COPD inflammation

Scope of Analysis
Objectives
Research methodology
- Extensive secondary research
- In-depth primary research
Analysis synthesis
Findings validation
Products analyzed
Disease description
- Key points
- Disease definition
- Symptom presentation
- Diagnosis
- Disease classification and definitions for this analysis
- Burden of disease
- Smoking and COPD
- Asthma and COPD
Treatment Map summary

Current Treatment Practice
Key findings & trends
- Inhaled short-acting ß2 agonists
- Inhaled short-acting muscarinic antagonist
- Combination inhaler of SABA + SAMA
- Inhaled long-acting ß2 agonist
- Inhaled long-acting muscarinic antagonist
- Single combination inhaler of LABA + inhaled corticosteroid
- Inhaled corticosteroids
- Phosphodiesterase-4 inhibitors
- Methylxanthines
- Alpha-1 antitrypsin augmentation therapy
- Oral corticosteroids
- Antibiotics
- Other pharmacological therapy options
- Non-pharmacological therapy
Inhaled short-acting ß2 agonist
Inhaled short-acting muscarinic antagonist
Single combination inhaler of SABA + SAMA
Inhaled long-acting ß2 agonist
Inhaled long-acting muscarinic antagonist
Combination inhaler of ICS + LABA
Phosphodiesterase-4 (PDE-4) inhibitor
Oral corticosteroids
Methylxanthine
Antibiotics
Alpha-1 antitrypsin augmentation therapy

Treatment Challenges
Key findings & trends
- Defining severity: is FEV1 enough?
- Early diagnosis
- Non-inhaled pharmacotherapy
- Finding effective treatments for Stage I Mild COPD
- Inhaled corticosteroids: finding its right place
- Combination therapy of LABA + LAMA
- Combination inhaler of ULABA + ICS
- Very severe COPD: have we got the best treatment?
- Treating the inflammation of COPD
- Prevention of exacerbations
Challenge matrix
Large impact, smaller patient groups
- Managing Stage IV, very severe COPD
- Therapy selection for GOLD Stage II patients
Small impact, smaller patient groups
- Treating COPD inflammation
Small impact, sizable patient groups
- Diagnosis and assessment
- Effective treatments for Stage I Mild COPD
- Adherence issues
Large impact, sizable patient groups
- Initiating inhaled long-acting ß2 agonist
- Inhaled corticosteroid therapy, a benefit or a risk?
- Management of exacerbations

List of tables

Table 1: Key current brands and pipeline products for the treatment of COPD, by drug class
Table 2: Key differentiating clinical features of asthma and COPD

List of figures

Figure 1: Step-up approach to the management of COPD
Figure 2: LAMA vs. LABA – current factors favor LAMA use
Figure 3: LAMA vs. ULABA – current factors favor LAMA use
Figure 4: Summary of COPD Treatment Map
Figure 5: Treatment Challenges in COPD

Note: Product cover images may vary from those shown

- UCB Pharma
- GSK
- Merck
- Dey
- AstraZeneca
- Sunovion
- Boehringer Ingelheim
- Sandoz
- Teva
- Novartis
- Chiesi
- Nycomed

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos